ABL Bio Inc.

298380· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

₩39,750+1.40%

2026-11-02

Financials

Valuation Metrics

ABL Bio Inc.'s Market Cap is ₩2.2T. At end of 2025 it was ₩11.2T. Ranked #177 of 2,405 in KR market (top 7%), #27 of 1,627 on KOSDAQ (top 2%), #13 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 6%) by Market Cap.

Investment Metrics(as of 2026-11-02)

Metric	Value	Rank
Size
Market Cap	2.23T KRW	KR#177/2,405 Sec#13/231
Revenue	34.28B KRW	KR#1,975/2,405 Sec#136/231
Net Income	-79.17B KRW	KR—/2,405 Sec—/231
Total Assets	273.72B KRW	KR#1,091/2,405 Sec#75/231
Net Assets	173.94B KRW	KR#1,036/2,405 Sec#72/231
Employees	104	KR#1,608/2,405 Sec#126/231
Value
P/B	12.79x	KR#2,374/2,405 Sec#218/231
P/S	64.92x	KR#2,366/2,405 Sec#201/231
FCF Yield	-1.86%	KR—/2,405 Sec—/231
Profitability
ROE	-45.51%	KR#2,250/2,405 Sec#192/231
ROA	-28.92%	KR#2,297/2,405 Sec#200/231
Op. Margin	-251.20%	KR#2,325/2,405 Sec#189/231
Revenue Growth	-63.89%	KR#2,298/2,405 Sec#209/231
Financial Health
Debt Ratio	57.37%	KR#1,058/2,405 Sec#124/231
Total Debt	55.00B KRW	KR#972/2,405 Sec#65/231
FCF	-41.38B KRW	KR#2,039/2,405 Sec#202/231
Cash	164.98B KRW	KR#316/2,405 Sec#13/231
Current Ratio	1.72x	KR#1,019/2,405 Sec#114/231
Performance
1Y Return	-60.13%	KR#2,181/2,405 Sec#205/231
1M Return	-22.67%	KR#1,998/2,405 Sec#195/231
From 52W High	-84.56%	KR#2,352/2,405 Sec#221/231
1Y MDD	-84.03%	KR#2,331/2,405 Sec#218/231
Trading
Volume	202,661 shares	KR#367/2,405 Sec#33/231
Trading Value	8.01B KRW	KR#231/2,405 Sec#16/231
Foreign Own.	13.48%	KR#359/2,405 Sec#24/231
Per Share
EPS	-1,414 KRW	KR—/2,405 Sec—/231
BPS	3,107 KRW	KR#1,851/2,405 Sec#138/231

Company Info

CEO 이상훈

Employees 104

Founded 2016

HQ 서울 강남구, KR

Website www.ablbio.com

동사는 2016년 설립돼 2018년 코스닥에 상장한 바이오의약품 연구개발 전문기업임. 이중항체 기술 플랫폼 'Grabody™'로 면역관문 조절, 신규 타깃 발굴, 퇴행성뇌질환 치료제, 항체-약물 접합체 등 항체치료제를 연구개발하고 있음. 경쟁력 있는 플랫폼과 다양한 파이프라인 확보, 기술이전을 통한 외형 확대와 엄격한 의사결정 체계를 적용하여 높은 가치 창출을 추구하고 있음. 에이비엘바이오는 2016년에 설립되었으며 서울 강남구에 본사를 두고 있습니다.